Sector Expert: Francois Brisebois

Laidlaw & Company



Recent Interviews

Coverage Initiated on Synthetic Cannabinoid Bioscience Company, an 'Exciting, Undiscovered Story' (6/29/17)
beakers blacknblue630.jpg

Laidlaw & Company initiated coverage with a Buy rating and target price of $18 on a company that is repurposing an approved cannabinoid to fulfill unmet medical needs.

Recent Quotes

"DRRX's capital raise takes care of financing overhang on the stock."

— Francois Brisebois, Laidlaw & Company (6/27/19)
more >

"We are encouraged by DRRX's clinical timeline remaining on track."

— Francois Brisebois, Laidlaw & Company (5/13/19)
more >

"DRRX's current valuation is an interesting buying opportunity."

— Francois Brisebois, Laidlaw & Company (3/8/19)
more >

"We are encouraged by DRRX's decision to fully respond to the CRL."

— Francois Brisebois, Laidlaw & Company (2/28/19)
more >

"DRRX will benefit from quarterly earnout payments on Perseris sales."

— Francois Brisebois, Laidlaw & Company (1/14/19)
more >

"DRRX intends to start a NASH trial as soon as H1/19."

— Francois Brisebois, Laidlaw & Company (11/8/18)
more >

"We consider DRRX a development story."

— Francois Brisebois, Laidlaw & Company (8/2/18)
more >

"FDA approval of Perseris triggers a $5M milestone payment to DRRX."

— Francois Brisebois, Laidlaw & Company (7/30/18)
more >

more comments

"We continue to view DRRX as undervalued and reiterate our Buy rating."

— Francois Brisebois, Laidlaw & Company (6/27/18)
more >

"DRRX reported its Q1/18, mostly in line with expectations."

— Francois Brisebois, Laidlaw & Company (5/3/18)
more >

"Two of DRRX's three Phase 2 DUR-928 trials should read out by 2018E."

— Francois Brisebois, Laidlaw & Company (3/2/18)
more >

"We believe 2018 could prove to be a pivotal year for DRRX."

— Francois Brisebois, Laidlaw & Company (11/2/17)
more >

"DRRX will initiate three Phase 2 trials in the near term."

— Francois Brisebois, Laidlaw & Company (10/20/17)
more >

"On the back of DRRX's solid deal with Sandoz and with more catalysts to come in 2017 such as Posimir Phase 3 readout in 4Q17 and IND filings for DUR-928, we see potential near-term upside."

— Francois Brisebois, Laidlaw & Company (8/9/17)
more >

fewer comments


Due to permission requirements, not all quotes are shown.